MVT-602 is an oligopeptide kisspeptin-1 receptor agonist that has the potential to be a safer alternative to human chorionic gonadotropin for the treatment of female infertility as part of assisted reproduction.



Kisspeptin, the ligand, is a naturally-occurring peptide that stimulates GnRH release and is required for puberty and maintenance of normal reproductive function, including production of sperm, follicular maturation and ovulation, and production of estrogen and progesterone in women and testosterone in men. MVT-602 is being developed as a potential treatment for female infertility as part of assisted reproduction, such as in vitro fertilization, or IVF.

Myovant is studying whether MVT-602, an oligopeptide kisspeptin-1 receptor agonist, may produce an LH surge in women needing assisted reproduction similar to that occurring naturally in fertile women during a normal menstrual cycle. By mimicking the natural physiologic LH surge during IVF and other assisted reproductive technologies, Myovant is evaluating the likelihood of successful egg maturation and ovulation at the right time without the serious side effect of ovarian hyper-stimulation syndrome, or OHSS. Severe OHSS has been reported to occur in up to 2% of the general population undergoing controlled ovarian stimulation, and in up to 20% of patients who are at high-risk for developing OHSS.

Further assessment of the exposure-response profile of MVT-602 is being conducted in a Phase 2a study in approximately 70 fertile women undergoing controlled ovarian stimulation. This study is intended to provide information for dose selection for a study of MVT-602 in infertile women seeking pregnancy.